Combining oncolytic virotherapy and tumour vaccination

被引：30

作者：

Bridle, Byram W. ^{[1
]}

Hanson, Stephen ^{[1
]}

Lichty, Brian D. ^{[1
]}

机构：

[1] McMaster Univ, Dept Pathol & Mol Med, Ctr Gene Therapeut, Hamilton, ON L8N 3Z5, Canada

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2010年 / 21卷 / 2-3期

关键词：

Oncolytic virus; Tumour vaccine; Prime: boost; Anti-tumour immunity; POTENT ANTITUMOR IMMUNITY; HERPES-SIMPLEX-VIRUS; REGULATORY T-CELLS; PROSTATIC ACID-PHOSPHATASE; VESICULAR STOMATITIS-VIRUS; RECOMBINANT VACCINIA VIRUS; DENDRITIC CELLS; CANCER-PATIENTS; DIVERSIFIED PRIME; COLORECTAL-CANCER;

D O I：

10.1016/j.cytogfr.2010.02.009

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The interactions between the immune system, a malignant tumour and an oncolytic virus are complex and poorly understood. For oncolytic viruses to become successful therapeutics we need to better understand these interactions and identify strategies to take advantage of defects in the innate immune response within tumours and avoid cellular anti-viral responses while capitalizing on anti-tumoural immunity. In this review we will discuss the evidence for the induction of tumour-specific immune responses by oncolytic viruses as well as by cancer vaccines. We will then describe some of the barriers to successful cancer immunotherapy, and finally we will outline a strategy for enhancing anti-tumoural immunity while reducing anti-viral immunity by combining tumour vaccination with oncolytic viral therapy. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：143 / 148

页数：6

共 79 条

[51] The 'short' history of regulatory B cells [J].

Mauri, Claudia ;

Ehrenstein, Michael R. .

TRENDS IN IMMUNOLOGY, 2008, 29 (01) :34-40

[52] Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer [J].

McNeel, Douglas G. ;

Dunphy, Edward J. ;

Davies, James G. ;

Frye, Thomas P. ;

Johnson, Laura E. ;

Staab, Mary Jane ;

Horvath, Dorothea L. ;

Straus, Jane ;

Alberti, Dona ;

Marnocha, Rebecca ;

Liu, Glenn ;

Eickhoff, Jens C. ;

Wilding, George .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4047-4054

[53]

MIYAZAWA M, 2009, CANC SCI

[54] Regulation of CD8+ T cell development by thymus-specific proteasomes [J].

Murata, Shigeo ;

Sasaki, Katsuhiro ;

Kishimoto, Toshihiko ;

Niwa, Shin-ichiro ;

Hayashi, Hidemi ;

Takahama, Yousuke ;

Tanaka, Keiji .

SCIENCE, 2007, 316 (5829) :1349-1353

[55] Clinical Considerations in Developing Dendritic Cell Vaccine Based Immunotherapy Protocols in Cancer [J].

Murthy, Vedang ;

Moiyadi, Aliasgar ;

Sawant, Rajesh ;

Sarin, Rajiv .

CURRENT MOLECULAR MEDICINE, 2009, 9 (06) :725-731

[56] Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity [J].

Nakamori, M ;

Fu, XP ;

Rousseau, R ;

Chen, SY ;

Zhang, XL .

MOLECULAR THERAPY, 2004, 9 (05) :658-665

[57] TGF-β1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice [J].

Nakamura, K ;

Kitani, A ;

Fuss, I ;

Pedersen, A ;

Harada, N ;

Nawata, H ;

Strober, W .

JOURNAL OF IMMUNOLOGY, 2004, 172 (02) :834-842

[58] Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor [J].

Naslund, Tanja I. ;

Uyttenhove, Catherine ;

Nordstrom, Eva K. L. ;

Colau, Didier ;

Warnier, Guy ;

Jondal, Mikael ;

Van den Eynde, Benoit J. ;

Liljestrom, Peter .

JOURNAL OF IMMUNOLOGY, 2007, 178 (11) :6761-6769

[59]

Ojima T, 2006, INT J ONCOL, V28, P947

[60]

Old Lloyd J, 2008, Cancer Immun, V8 Suppl 1, P1

← 1 2 3 4 5 6 7 8 →